Careers  |  Sign In  |  Register  |   Twitter

Targeting Alpha-Synuclein with Antibodies to Treat Parkinson’s

Anthony Lang, OC, MD, FRCPC, FAAN, FCAHS, FRSC, Director of the Movement Disorders Clinic at the Krembil Neuroscience Center, discusses the investigational treatment PRX002 and other antibodies for the management of movement disorders like Parkinson’s Disease.

This type of treatment could potentially have an impact on all features of Parkinson’s related to the damage of nerve cells. Dr. Lang also mentions the possibility of vaccinations for the disease and discusses why there are none currently available.